Matching articles for "glycopyrrolate"

Drugs for COPD

   
The Medical Letter on Drugs and Therapeutics • September 2, 2024;  (Issue 1710)
The main goals of treatment of chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, prevent disease progression, and reduce...
The main goals of treatment of chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, prevent disease progression, and reduce mortality. GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines for treatment of COPD were updated recently. Treatment of acute exacerbations is not discussed here. Drugs available for treatment of COPD are listed in Tables 1 and 3.
Med Lett Drugs Ther. 2024 Sep 2;66(1710):137-44 | Show Full IntroductionHide Full Introduction

Comparison Table: Inhaled Drugs for Treatment of COPD (online only)

   
The Medical Letter on Drugs and Therapeutics • September 2, 2024;  (Issue 1710)
...
View the Comparison Table: Inhaled Drugs for Treatment of COPD
Med Lett Drugs Ther. 2024 Sep 2;66(1710):e143-7 | Show Full IntroductionHide Full Introduction

Sofpironium (Sofdra) for Primary Axillary Hyperhidrosis

   
The Medical Letter on Drugs and Therapeutics • August 19, 2024;  (Issue 1709)
The FDA has approved a 12.45% gel formulation of the anticholinergic drug sofpironium (Sofdra – Botanix) for treatment of primary axillary hyperhidrosis (excessive underarm sweating) in patients ≥9 years...
The FDA has approved a 12.45% gel formulation of the anticholinergic drug sofpironium (Sofdra – Botanix) for treatment of primary axillary hyperhidrosis (excessive underarm sweating) in patients ≥9 years old.
Med Lett Drugs Ther. 2024 Aug 19;66(1709):133-4 | Show Full IntroductionHide Full Introduction

Brella Sweat Control Patch for Primary Axillary Hyperhidrosis (online only)

   
The Medical Letter on Drugs and Therapeutics • July 22, 2024;  (Issue 1707)
Brella Sweat Control Patch (Candesant Biomedical), a sodium-containing transdermal patch, has been cleared by the FDA for in-office treatment of primary axillary hyperhidrosis in adults. It is the first...
Brella Sweat Control Patch (Candesant Biomedical), a sodium-containing transdermal patch, has been cleared by the FDA for in-office treatment of primary axillary hyperhidrosis in adults. It is the first patch to be approved in the US for this indication.
Med Lett Drugs Ther. 2024 Jul 22;66(1707):e125-6 | Show Full IntroductionHide Full Introduction

Glycopyrrolate (Dartisla ODT) for Peptic Ulcer Symptoms

   
The Medical Letter on Drugs and Therapeutics • February 7, 2022;  (Issue 1643)
The FDA has approved adjunctive treatment with Dartisla ODT (Edenbridge), a new orally disintegrating tablet (ODT) formulation of the anticholinergic drug glycopyrrolate, to reduce symptoms of a peptic...
The FDA has approved adjunctive treatment with Dartisla ODT (Edenbridge), a new orally disintegrating tablet (ODT) formulation of the anticholinergic drug glycopyrrolate, to reduce symptoms of a peptic ulcer. Glycopyrrolate oral tablets (Robinul, Robinul Forte, and generics) were approved for the same indication in 1961.
Med Lett Drugs Ther. 2022 Feb 7;64(1643):24 | Show Full IntroductionHide Full Introduction

Drugs for COPD

   
The Medical Letter on Drugs and Therapeutics • September 7, 2020;  (Issue 1606)
The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Several...
The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Several guidelines and review articles on COPD treatment have been published in recent years. Treatment of acute exacerbations is not discussed here.
Med Lett Drugs Ther. 2020 Sep 7;62(1606):137-44 | Show Full IntroductionHide Full Introduction

Comparison Table: Inhaled Long-Acting Bronchodilators for Treatment of COPD (online only)

   
The Medical Letter on Drugs and Therapeutics • September 7, 2020;  (Issue 1606)
...
View the Comparison Table: Inhaled Long-Acting Bronchodilators for Treatment of COPD
Med Lett Drugs Ther. 2020 Sep 7;62(1606):e146-7 | Show Full IntroductionHide Full Introduction

Comparison Table: Inhaled Corticosteroids for Treatment of COPD (online only)

   
The Medical Letter on Drugs and Therapeutics • September 7, 2020;  (Issue 1606)
...
View the Comparison Table: Inhaled Corticosteroids for Treatment of COPD
Med Lett Drugs Ther. 2020 Sep 7;62(1606):e148-9 | Show Full IntroductionHide Full Introduction

Table: Correct Use of Inhalers for COPD (online only)

   
The Medical Letter on Drugs and Therapeutics • September 7, 2020;  (Issue 1606)
...
View the Table: Correct Use of Inhalers for COPD
Med Lett Drugs Ther. 2020 Sep 7;62(1606):e150-4 | Show Full IntroductionHide Full Introduction

Duaklir Pressair: Another LAMA/LABA Inhaler for COPD

   
The Medical Letter on Drugs and Therapeutics • September 23, 2019;  (Issue 1581)
The FDA has approved Duaklir Pressair (Circassia), a fixed-dose combination of the long-acting muscarinic antagonist (LAMA) aclidinium bromide and the longacting beta2-adrenergic agonist (LABA)...
The FDA has approved Duaklir Pressair (Circassia), a fixed-dose combination of the long-acting muscarinic antagonist (LAMA) aclidinium bromide and the longacting beta2-adrenergic agonist (LABA) formoterol fumarate, for maintenance treatment of chronic obstructive pulmonary disease (COPD). Aclidinium/formoterol is the fifth LAMA/LABA combination to be approved in the US for this indication.
Med Lett Drugs Ther. 2019 Sep 23;61(1581):149-51 | Show Full IntroductionHide Full Introduction

Revefenacin (Yupelri) for COPD

   
The Medical Letter on Drugs and Therapeutics • January 28, 2019;  (Issue 1564)
The FDA has approved revefenacin (Yupelri – Mylan/Theravance Biopharma), a long-acting antimuscarinic agent (LAMA) administered once daily by standard jet nebulizer, for maintenance treatment of...
The FDA has approved revefenacin (Yupelri – Mylan/Theravance Biopharma), a long-acting antimuscarinic agent (LAMA) administered once daily by standard jet nebulizer, for maintenance treatment of chronic obstructive pulmonary disease (COPD). Revefenacin is the second nebulized LAMA to be approved for this indication; glycopyrrolate (Lonhala Magnair), which is administered twice daily with a portable handheld nebulizer, was the first.
Med Lett Drugs Ther. 2019 Jan 28;61(1564):14-5 | Show Full IntroductionHide Full Introduction

Qbrexza - A Glycopyrronium Cloth for Axillary Hyperhidrosis

   
The Medical Letter on Drugs and Therapeutics • January 28, 2019;  (Issue 1564)
Qbrexza (Dermira), a premoistened cloth containing the long-acting anticholinergic drug glycopyrronium, has been approved by the FDA for once-daily topical treatment of excessive underarm sweating...
Qbrexza (Dermira), a premoistened cloth containing the long-acting anticholinergic drug glycopyrronium, has been approved by the FDA for once-daily topical treatment of excessive underarm sweating (primary axillary hyperhidrosis) in patients ≥9 years old. Glycopyrronium bromide (glycopyrrolate) has been available for years in parenteral, inhalation, and oral formulations for treatment of multiple conditions.
Med Lett Drugs Ther. 2019 Jan 28;61(1564):10-1 | Show Full IntroductionHide Full Introduction

Trelegy Ellipta - A Three-Drug Inhaler for COPD

   
The Medical Letter on Drugs and Therapeutics • May 21, 2018;  (Issue 1547)
The FDA has approved Trelegy Ellipta (GSK), a fixed-dose combination of the inhaled corticosteroid (ICS) fluticasone furoate, the long-acting antimuscarinic agent (LAMA) umeclidinium, and the...
The FDA has approved Trelegy Ellipta (GSK), a fixed-dose combination of the inhaled corticosteroid (ICS) fluticasone furoate, the long-acting antimuscarinic agent (LAMA) umeclidinium, and the long-acting beta2-agonist (LABA) vilanterol. It is available as a dry powder inhaler for once-daily maintenance treatment of COPD and to reduce COPD exacerbations in patients with a history of exacerbations. Trelegy Ellipta is the first three-drug inhaler for treatment of COPD to become available in the US.
Med Lett Drugs Ther. 2018 May 21;60(1547):86-8 | Show Full IntroductionHide Full Introduction

Nebulized Glycopyrrolate (Lonhala Magnair) for COPD

   
The Medical Letter on Drugs and Therapeutics • April 23, 2018;  (Issue 1545)
The FDA has approved an inhalation solution formulation of the long-acting antimuscarinic agent (LAMA) glycopyrrolate (Lonhala Magnair – Sunovion) for maintenance treatment of chronic...
The FDA has approved an inhalation solution formulation of the long-acting antimuscarinic agent (LAMA) glycopyrrolate (Lonhala Magnair – Sunovion) for maintenance treatment of chronic obstructive pulmonary disease (COPD). The new formulation is delivered using a portable, handheld, electronic nebulizer. Glycopyrrolate is also available as a dry powder inhaler, both alone (Seebri Neohaler) and in combination with indacaterol (Utibron Neohaler), and as a metered-dose inhaler in combination with formoterol (Bevespi Aerosphere). Lonhala Magnair is the first nebulized LAMA to become available in the US.
Med Lett Drugs Ther. 2018 Apr 23;60(1545):72 | Show Full IntroductionHide Full Introduction

Drugs for COPD

   
The Medical Letter on Drugs and Therapeutics • April 10, 2017;  (Issue 1518)
The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Updated...
The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Updated guidelines for treatment of COPD have been published in recent years.
Med Lett Drugs Ther. 2017 Apr 10;59(1518):57-62 | Show Full IntroductionHide Full Introduction

Comparison Table: Inhaled Long-Acting Bronchodilators for COPD (online only)

   
The Medical Letter on Drugs and Therapeutics • April 10, 2017;  (Issue 1518)
...
View the Comparison Table: Inhaled Long-Acting Bronchodilators for COPD
Med Lett Drugs Ther. 2017 Apr 10;59(1518):e64-5 | Show Full IntroductionHide Full Introduction

Table: Correct Use of Inhalers for COPD (online only)

   
The Medical Letter on Drugs and Therapeutics • April 10, 2017;  (Issue 1518)
...
View the Table: Correct Use of Inhalers for COPD
Med Lett Drugs Ther. 2017 Apr 10;59(1518):e67-71 | Show Full IntroductionHide Full Introduction

Glycopyrrolate/Formoterol (Bevespi Aerosphere) for COPD

   
The Medical Letter on Drugs and Therapeutics • October 10, 2016;  (Issue 1505)
The FDA has approved a fixed-dose combination of the long-acting anticholinergic glycopyrrolate and the long-acting beta2-adrenergic agonist (LABA) formoterol (Bevespi Aerosphere – AstraZeneca)...
The FDA has approved a fixed-dose combination of the long-acting anticholinergic glycopyrrolate and the long-acting beta2-adrenergic agonist (LABA) formoterol (Bevespi Aerosphere – AstraZeneca) for long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Glycopyrrolate/formoterol is the fourth long-acting anticholinergic/LABA combination to be approved in the US, but the first to become available in a metered-dose inhaler. Glycopyrrolate/indacaterol (Utibron Neohaler), umeclidinium/vilanterol (Anoro Ellipta), and tiotropium/olodaterol (Stiolto Respimat) were approved earlier.
Med Lett Drugs Ther. 2016 Oct 10;58(1505):130-2 | Show Full IntroductionHide Full Introduction

Seebri Neohaler and Utibron Neohaler for COPD

   
The Medical Letter on Drugs and Therapeutics • March 28, 2016;  (Issue 1491)
The FDA has approved two new inhalers for long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). Seebri Neohaler (Novartis) contains the long-acting anticholinergic glycopyrrolate....
The FDA has approved two new inhalers for long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). Seebri Neohaler (Novartis) contains the long-acting anticholinergic glycopyrrolate. Utibron Neohaler (Novartis) contains both glycopyrrolate and the long-acting beta2-adrenergic agonist (LABA) indacaterol. Glycopyrrolate/indacaterol is the third fixed-dose combination of a long-acting anticholinergic and a LABA to become available in the US; umeclidinium/vilanterol (Anoro Ellipta) and tiotropium/olodaterol (Stiolto Respimat) were approved earlier.
Med Lett Drugs Ther. 2016 Mar 28;58(1491):39-41 | Show Full IntroductionHide Full Introduction

Tiotropium/Olodaterol (Stiolto Respimat) for COPD

   
The Medical Letter on Drugs and Therapeutics • November 23, 2015;  (Issue 1482)
The FDA has approved a fixed-dose, orally inhaled combination of the long-acting anticholinergic tiotropium and the long-acting beta2-adrenergic agonist olodaterol (Stiolto Respimat — Boehringer...
The FDA has approved a fixed-dose, orally inhaled combination of the long-acting anticholinergic tiotropium and the long-acting beta2-adrenergic agonist olodaterol (Stiolto Respimat — Boehringer Ingelheim) for long-term, once-daily, maintenance treatment of airflow obstruction in chronic obstructive pulmonary disease (COPD). It is not approved for treatment of acute exacerbations of COPD or for treatment of asthma. Tiotropium (Spiriva Handihaler, Spiriva Respimat) and olodaterol (Striverdi Respimat) are also available separately for once-daily treatment of COPD.
Med Lett Drugs Ther. 2015 Nov 23;57(1482):161-2 | Show Full IntroductionHide Full Introduction

In Brief: Glycopyrrolate Oral Solution for Sialorrhea

   
The Medical Letter on Drugs and Therapeutics • January 10, 2011;  (Issue 1355)
Glycopyrrolate (Robinul, and others), a synthetic muscarinic receptor antagonist, has been used off-label for many years for treatment of excessive drooling in patients with Parkinson’s disease, in patients...
Glycopyrrolate (Robinul, and others), a synthetic muscarinic receptor antagonist, has been used off-label for many years for treatment of excessive drooling in patients with Parkinson’s disease, in patients taking clozapine for schizophrenia, and in developmentally disabled children.1-3 It has now been approved by the FDA as Cuvposa (Shionogi) for use specifically in children 3-16 years old with severe chronic drooling due to a neurologic condition, such as cerebral palsy. It is being marketed as an oral solution, which will permit more precise weight-based dosing than was possible with the oral tablets used in the past. As with other anticholinergic drugs, dry mouth, constipation, flushing and nasal congestion can occur. Since glycopyrrolate decreases secretion not only of saliva, but also of sweat, overheating due to high ambient temperatures or excessive exercise could be dangerous for patients who take it.

1. ME Arbouw et al. Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial. Neurology 2010; 74:1203.

2. CS Liang et al. Comparison of the efficacy and impact on cognition of glycopyrrolate and biperiden for clozapine-induced sialorrhea in schizophrenic patients: a randomized, double-blind, crossover study. Schizophren Res 2010; 119:138.

3. RJ Mier et al. Treatment of sialorrhea with glycopyrrolate: a double-blind, dose-ranging study. Arch Pediatr Adolesc Med 2000; 154:1214.

Download U.S. English
Med Lett Drugs Ther. 2011 Jan 10;53(1355):4 | Show Full IntroductionHide Full Introduction